ALPS Medical Breakthroughs ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week0.27%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month6.35%
Income- PEG- EPS next Q- Inst Own- Short Float / Ratio- / - Perf Quarter10.68%
Sales- P/S- EPS this Y- Inst Trans- Short Interest- Perf Half Y-6.67%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-4.00%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range23.58 - 37.38 Perf YTD7.53%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-12.61% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low38.54% ATR0.66
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)59.32 Volatility1.85% 1.94%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.48 Prev Close32.50
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume21.80K Price32.67
Recom- SMA202.27% SMA506.29% SMA2008.91% Volume10,508 Change0.52%
Jun-30-22 08:51AM
Apr-04-22 07:30AM
Mar-24-22 08:42AM
Mar-22-22 07:00AM
Aug-20-20 04:58PM
11:10AM Loading…
Jun-23-20 11:10AM
Apr-14-20 04:00PM
Feb-21-20 11:42AM
Feb-10-20 01:40PM
Dec-26-19 02:30PM
Dec-24-19 12:15PM
Dec-23-19 12:00PM
Dec-20-19 02:00PM
Dec-12-19 08:00AM
Dec-10-19 04:16PM
10:10AM Loading…
Dec-02-19 02:40PM
Nov-27-19 11:05AM
Nov-21-19 12:15PM
Nov-01-19 11:10AM
Oct-31-19 12:25PM
Oct-30-19 10:43AM
Oct-23-19 04:24PM
Sep-09-19 04:55PM
Sep-03-19 05:46PM
Aug-05-19 12:00PM
Jun-24-19 04:23PM
Jun-18-19 09:55AM
03:22PM Loading…
Jun-17-19 03:22PM
May-15-19 01:00PM
May-06-19 06:05PM
Apr-11-19 03:33PM
Apr-10-19 03:21PM
Mar-06-19 05:05PM
Feb-28-19 01:00PM
Feb-27-19 03:00PM
Feb-26-19 11:15AM
Feb-25-19 01:59PM
Feb-14-19 01:53PM
Jan-23-19 09:16AM
Jan-22-19 10:15AM
Jan-14-19 01:00PM
Jan-07-19 01:56PM
Dec-27-18 02:30PM
Nov-20-18 02:03PM
Oct-23-18 09:18AM
Oct-10-18 03:30PM
Sep-28-18 07:37AM
Sep-06-18 11:00AM
Jul-12-18 03:23PM
Jul-03-18 04:42PM
Jul-02-18 03:23PM
Jun-28-18 12:25PM
May-31-18 04:36PM
May-21-18 02:20PM
May-11-18 04:18PM
Apr-16-18 08:00AM
Mar-27-18 12:42PM
Jan-11-18 10:57AM
Jan-10-18 12:18PM
Dec-28-17 02:27PM
Dec-22-17 04:16PM
Sep-12-17 03:08PM
Aug-29-17 12:44PM
Aug-28-17 02:37PM
Jul-06-17 06:07PM
Jun-19-17 05:18PM
Jun-01-17 01:12PM
May-18-17 10:19AM
May-08-17 05:42PM
Mar-21-17 12:19PM
Mar-01-17 04:14PM
Feb-23-17 11:45AM
Jan-12-17 12:00PM
Dec-08-16 03:00PM
Nov-14-16 01:54PM
Nov-10-16 09:55AM
Nov-01-16 12:46PM
Oct-27-16 12:19PM
Oct-21-16 09:54AM
Sep-21-16 11:23AM
Sep-14-16 02:19PM
Sep-12-16 02:47PM
Aug-19-16 12:14PM
Aug-01-16 08:00AM
Jul-20-16 02:23PM
Jul-05-16 10:53AM
Jun-22-16 10:40AM
Apr-15-16 11:33AM
Apr-07-16 11:30AM
Apr-06-16 11:38AM
Feb-05-16 09:48AM
Feb-03-16 01:05PM
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.